These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 11062751)

  • 21. Hepatic arterial continuous infusion (HACI) of oxaliplatin in patients with unresectable liver metastases from colorectal cancer.
    Mancuso A; Giuliani R; Accettura C; Palma M; D'Auria G; Cecere F; Paoluzzi L; Bezzi M; Massidda B; Cortesi E
    Anticancer Res; 2003; 23(2C):1917-22. PubMed ID: 12820479
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oxaliplatin may induce cytokine-release syndrome in colorectal cancer patients.
    Tonini G; Santini D; Vincenzi B; Borzomati D; Dicuonzo G; La Cesa A; Onori N; Coppola R
    J Biol Regul Homeost Agents; 2002; 16(2):105-9. PubMed ID: 12144121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thermal enhancement of oxaliplatin-induced inhibition of cell proliferation and cell cycle progression in human carcinoma cell lines.
    Atallah D; Marsaud V; Radanyi C; Kornprobst M; Rouzier R; Elias D; Renoir JM
    Int J Hyperthermia; 2004 Jun; 20(4):405-19. PubMed ID: 15204521
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
    Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
    Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines.
    Yang AD; Fan F; Camp ER; van Buren G; Liu W; Somcio R; Gray MJ; Cheng H; Hoff PM; Ellis LM
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4147-53. PubMed ID: 16857785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Results of hepatic arterial infusion chemotherapy with 5-FU and leucovorin for unresectable liver metastases from colorectal cancer].
    Yamashita K; Urakami A; Kubota H; Nagatsuka R; Murakami H; Kawabe Y; Higashida M; Hirabayashi Y; Mikami Y; Ikeda M; Fuchimoto M; Yamamura M; Oka Y; Okumura H; Iki K; Matsumoto H; Imai S; Hirai T; Tsunoda T
    Gan To Kagaku Ryoho; 2008 Jan; 35(1):71-6. PubMed ID: 18195531
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Combined chemotherapy with oral leucovorin (LV) + tegafur/uracil (UFT) and hepatic arterial infusion (HAI) therapy for liver metastasis of colorectal cancer].
    Hasegawa S; Matsumoto S; Kawashima K; Fujii H; Hatano E; Satoh S; Ikai I; Shimahara Y
    Gan To Kagaku Ryoho; 2005 Jul; 32(7):1045-9. PubMed ID: 16044971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase II study of radiofrequency ablation of unresectable metastatic colorectal cancer with hepatic arterial infusion pump chemotherapy.
    Martin RC; Scoggins CR; McMasters KM
    J Surg Oncol; 2006 Apr; 93(5):387-93. PubMed ID: 16550574
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospective pilot study of neoadjuvant chemotherapy with 5-fluorouracil, folinic acid and oxaliplatin in resectable liver metastases of colorectal cancer. Analysis of 42 neoadjuvant chemotherapies.
    Lorenz M; Staib-Sebler E; Gog C; Proschek D; Jauch KW; Ridwelski K; Hohenberger W; Gassel HJ; Lehmann U; Vestweber KH; Padberg W; Zamzow K; Müller HH
    Zentralbl Chir; 2003 Feb; 128(2):87-94. PubMed ID: 12632273
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regional chemotherapy: a focus on hepatic artery infusion for colorectal cancer liver metastases.
    Dizon DS; Schwartz J; Kemeny N
    Surg Oncol Clin N Am; 2008 Oct; 17(4):759-71, viii. PubMed ID: 18722916
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Superior cytotoxicity and DNA cross-link induction by oxaliplatin versus cisplatin at lower cellular uptake in colorectal cancer cell lines.
    Virag P; Perde-Schrepler M; Fischer-Fodor E; Tatomir C; Dorneanu SA; Cernea VI; Irimie A
    Anticancer Drugs; 2012 Nov; 23(10):1032-8. PubMed ID: 22614106
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II feasibility study on the combination of two different regional treatment approaches in patients with colorectal "liver-only" metastases: hepatic interstitial brachytherapy plus regional chemotherapy.
    Wieners G; Pech M; Hildebrandt B; Peters N; Nicolaou A; Mohnike K; Seidensticker M; Sawicki M; Wust P; Ricke J
    Cardiovasc Intervent Radiol; 2009 Sep; 32(5):937-45. PubMed ID: 19472000
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nerve growth factor exerts differential effects on the growth of human pancreatic cancer cells.
    Zhu ZW; Friess H; Wang L; Bogardus T; Korc M; Kleeff J; Büchler MW
    Clin Cancer Res; 2001 Jan; 7(1):105-12. PubMed ID: 11205897
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro schedule-dependent interaction between melphalan and oxaliplatin in human colorectal cancer cell lines.
    van Iersel LB; Koudijs TM; Hoekman EJ; Janssen-van Rhijn CM; Vahrmeijer AL; Nortier JW; van de Velde CJ; Gelderblom H; Kuppen PJ
    J Surg Res; 2011 May; 167(2):273-8. PubMed ID: 20036390
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatic arterial infusion alternating with systemic chemotherapy in patients with non-resectable hepatic metastases from colorectal cancer.
    Kim JC; Kim HC; Lee KH; Yu CS; Kim TW; Chang HM; Ryu MH; Kim JH; Ha HK; Lee MG
    J Gastroenterol Hepatol; 2006 Jun; 21(6):1026-35. PubMed ID: 16724990
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatic arterial infusion for unresectable colorectal liver metastases combined or not with systemic chemotherapy.
    Pilati P; Mammano E; Mocellin S; Tessari E; Lise M; Nitti D
    Anticancer Res; 2009 Oct; 29(10):4139-44. PubMed ID: 19846962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A retrospective study of bifractionated CPT-11 with LF5FU infusion (FOLFIRI-3) in colorectal cancer patients pretreated with oxaliplatin and CPT-11 containing chemotherapies.
    Viel E; Demarchi MF; Chaigneau L; Nguyen T; Legat C; Stein U; Thiery-Vuillemin A; Limat S; Pivot X; Borg C
    Am J Clin Oncol; 2008 Feb; 31(1):89-94. PubMed ID: 18376234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The potential for a selective cyclooxygenase-2 inhibitor in the prevention of liver metastasis in human colorectal cancer.
    Yamauchi T; Watanabe M; Hasegawa H; Nishibori H; Ishii Y; Tatematsu H; Yamamoto K; Kubota T; Kitajima M
    Anticancer Res; 2003; 23(1A):245-9. PubMed ID: 12680220
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HDAC inhibitors, MS275 and SBHA, enhances cytotoxicity induced by oxaliplatin in the colorectal cancer cell lines.
    Flis S; Gnyszka A; Spławiński J
    Biochem Biophys Res Commun; 2009 Sep; 387(2):336-41. PubMed ID: 19596269
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of preoperative chemotherapy in patients with resectable colorectal liver metastases.
    Benoist S; Nordlinger B
    Ann Surg Oncol; 2009 Sep; 16(9):2385-90. PubMed ID: 19554377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.